Advertisement

Applicability of the modified CHA2DS2-VASc score for stroke risk stratification in Caucasian atrial fibrillation patients

Published:November 15, 2016DOI:https://doi.org/10.1016/j.ejim.2016.11.006
      Since 2010, guidelines recommend the use of the CHA2DS2-VASc score to estimate stroke risk in non-valvular atrial fibrillation (AF) patients [
      • Kirchof P.
      • Benussi S.
      • Kotecha D.
      • Ahlsson A.
      • Atar D.
      • Casadei B.
      • et al.
      2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
      ]. The CHA2DS2-VASc is a simple, clinical risk factor-based approach to thromboprophylaxis, which has been validated in different cohorts and is widely used [
      • Lip G.Y.
      • Nieuwlaat R.
      • Pisters R.
      • Lane D.A.
      • Crijns H.J.
      Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
      ]. It has shown to help identify individuals with truly low thromboembolic risk (i.e. CHA2DS2-VASc score of 0 for men or 1 for women), who require no anticoagulation, thus simplifying anticoagulation decision-making [
      • Coppens M.
      • Eikelboom J.W.
      • Hart R.G.
      • Yusuf S.
      • Lip G.Y.
      • Dorian P.
      • et al.
      The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kirchof P.
        • Benussi S.
        • Kotecha D.
        • Ahlsson A.
        • Atar D.
        • Casadei B.
        • et al.
        2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; https://doi.org/10.1093/eurheartj/ehw210
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Coppens M.
        • Eikelboom J.W.
        • Hart R.G.
        • Yusuf S.
        • Lip G.Y.
        • Dorian P.
        • et al.
        The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
        Eur Heart J. 2013; 34: 170-176
        • Siu C.W.
        • Lip G.Y.
        • Lam K.F.
        • Tse H.F.
        Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong.
        Heart Rhythm. 2014; 11: 1401-1408
        • Chao T.F.
        • Wang K.L.
        • Liu C.J.
        • Lin Y.J.
        • Chang S.L.
        • Lo L.W.
        • et al.
        Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan.
        J Am Coll Cardiol. 2015; 66: 1339-1347
        • Chao T.F.
        • Lip G.Y.H.
        • Liu C.J.
        • Tuan T.C.
        • Chen S.J.
        • Wang K.L.
        • et al.
        Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation. A nationwide cohort study.
        Stroke. 2016; 47: 2462-2469